BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 25407774)

  • 1. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.
    Figarella-Branger D; Mokhtari K; Colin C; Uro-Coste E; Jouvet A; Dehais C; Carpentier C; Villa C; Maurage CA; Eimer S; Polivka M; Vignaud JM; Laquerriere A; Sevestre H; Lechapt-Zalcman E; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Viennet G; Adam C; Loussouarn D; Michalak S; Rigau V; Heitzmann A; Vandenbos F; Forest F; Chiforeanu D; Tortel MC; Labrousse F; Chenard MP; Nguyen AT; Varlet P; Kemeny JL; Levillain PM; Cazals-Hatem D; Richard P; Delattre JY;
    Brain Pathol; 2015 Jul; 25(4):418-28. PubMed ID: 25407774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
    Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
    Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
    Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
    J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status.
    Mellai M; Annovazzi L; Senetta R; Dell'Aglio C; Mazzucco M; Cassoni P; Schiffer D
    J Neurooncol; 2017 Jan; 131(2):213-222. PubMed ID: 27796734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution.
    Jiang H; Ren X; Wang J; Zhang Z; Jia W; Lin S
    J Neurooncol; 2014 Jan; 116(2):395-404. PubMed ID: 24264532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report.
    Takami H; Mukasa A; Takayanagi S; Koike T; Matsuura R; Ikemura M; Ushiku T; Yoshikawa G; Shibahara J; Tanaka S; Saito N
    Brain Tumor Pathol; 2023 Jan; 40(1):26-34. PubMed ID: 36572828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
    Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
    Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S
    Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular classification of low-grade diffuse gliomas.
    Kim YH; Nobusawa S; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Vital A; Mariani L; Stawski R; Watanabe T; De Girolami U; Kleihues P; Ohgaki H
    Am J Pathol; 2010 Dec; 177(6):2708-14. PubMed ID: 21075857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
    Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
    Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.
    Boots-Sprenger SH; Sijben A; Rijntjes J; Tops BB; Idema AJ; Rivera AL; Bleeker FE; Gijtenbeek AM; Diefes K; Heathcock L; Aldape KD; Jeuken JW; Wesseling P
    Mod Pathol; 2013 Jul; 26(7):922-9. PubMed ID: 23429602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of chromosome 1p and 19q status and expression of R132H mutant IDH1 protein in oligodendroglial tumors].
    Yao K; Duan Z; Hu Z; Bian Y; Qi X
    Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):663-7. PubMed ID: 25567591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.
    Laxton RC; Popov S; Doey L; Jury A; Bhangoo R; Gullan R; Chandler C; Brazil L; Sadler G; Beaney R; Sibtain N; King A; Bodi I; Jones C; Ashkan K; Al-Sarraj S
    Neuro Oncol; 2013 Dec; 15(12):1635-43. PubMed ID: 24158110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
    Rajmohan KS; Sugur HS; Shwetha SD; Ramesh A; Thennarasu K; Pandey P; Arivazhagan A; Santosh V
    J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients.
    Ren X; Cui X; Lin S; Wang J; Jiang Z; Sui D; Li J; Wang Z
    PLoS One; 2012; 7(3):e32764. PubMed ID: 22427879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
    Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
    Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D
    J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.